Related Experiment Video
Updated: Apr 27, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
An observational, retrospective, UK and Ireland audit of patient adherence to subcutaneous interferon beta-1a
Helen Willis1, Julie Webster1, Anne Marie Larkin2
1Broomfield Hospital, Chelmsford, Essex, United Kingdom.
Background:
Poor adherence to disease-modifying drugs is associated with an increased risk of relapse in patients with multiple sclerosis. However, adherence is difficult to assess objectively. RebiSmart(®) (Merck Serono SA, Geneva, Switzerland), a device for subcutaneous (sc) injection of interferon (IFN) β-1a, features an electronic injection log that can assist in objective monitoring of adherence.
Objective:
To assess adherence to sc IFN β-1a injections using data from RebiSmart(®).
Methods:
This was a single-group, observational, retrospective audit. Adherence data were collected from patients with relapsing multiple sclerosis in the United Kingdom and Ireland who had been prescribed sc IFN β-1a and had been using RebiSmart(®) for a minimum of 24 months.
Results:
In total, 225 patients were included in the full analysis set; 72% were in the United Kingdom, and 28% were in Ireland. Overall, the mean age was 44.1 years, and 73% were women. Patients received sc IFN β-1a 44 µg (68%) or 22 µg (32%) three times per week. Mean adherence over the course of 24 months was 95.0% (median, 99.4%), and similar values were observed across all periods. The proportion of patients with 80% or higher adherence was 92.0% at 12 months and 91.1% at 24 months.
Conclusion:
High adherence to sc IFN β-1a was observed across all patient groups using RebiSmart(®), according to 2-year treatment adherence data. This may be partly attributed to the expert support patients received, supplemented by routine and regular contact from the MySupport patient-support program, as well as the self-motivation of patients who persisted with treatment for 2 or more years.
More Related Videos
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into...
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
Bioequivalence studies: Biowaivers
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

